Wegovy has raised concerns for investors in the food and beverage industry. Anheuser-Busch InBev (BUD) CEO Michel Doukeris tells Yahoo Finance Brian Sozzi that he thinks beer is immune to consumers' ...
Omega Therapeutics Inc. says its CEO, Mahesh Karande, has decided to leave the company for what it called "personal reasons,” ...
Shares in major pharmaceutical companies are down as well: Pfizer has fallen 4.6 percent, Eli Lilly 4.2 percent, Amgen 4.9 ...
The company's revenue jumped 77% in Q3 to reach $401.6 million in Q3 2024, alongside a net income of $75.6 million. It now ...
Vaccine maker Bavarian Nordic expects the incoming Trump administration to boost biodefence funding despite the nomination of ...
Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced recent transactions involving its shares by board members and executives, highlighting an acquisition of 18,634 shares and a sale ...
Research and Development (R&D) Expenses: R&D expenses were $16.0 million for the three months ended September 30, 2024, as compared to $14.0 million for the same period in 2023. The increase was ...
If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback